Screener
Beam Therapeutics BEAM EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
FAQ
- What is Beam Therapeutics's EPS (diluted)?
- Beam Therapeutics (BEAM) reported EPS (diluted) of -$0.91 in Q1 2026.
- How has Beam Therapeutics's EPS (diluted) changed year-over-year?
- Beam Therapeutics's EPS (diluted) increased by 26.0% year-over-year, from -$1.23 to -$0.91.
- What is the long-term trend for Beam Therapeutics's EPS (diluted)?
- Over 2 years (2021 to 2024), Beam Therapeutics's EPS (diluted) has grown at a -12.0% compound annual growth rate (CAGR), from -$5.91 to -$4.58.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Beam Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude